Emergent gets $120M U.S. government order for smallpox vaccine ACAM2000, plus $60.6M for VIGIV

Emergent BioSolutions Inc.

ASPR exercises third annual option under 10-year, ~$2B contract; $120M for ACAM2000 doses due by June 30, 2023.
Separate contract option for VIGIV (smallpox treatment) valued at approximately $60.6M also secured.
Order follows prior NOIPs for ACAM2000, VIGIV, and BAT; strengthens U.S. Strategic National Stockpile.
Volume is smaller than prior years but supports Emergent's 2023 financial outlook and domestic manufacturing.
SVP Paul Williams highlights importance of public-private partnerships in biodefense preparedness.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Emergent BioSolutions Inc. amended Third Option Exercise with Office of the Assistant Secretary for Preparedness and Response (ASPR), an agency of the U.S. Department of Health and Human Services (HHS) valued at approximately $120 million (effective 2023-05-26).

Action: amendment
Agreement: supply
Counterparty: Office of the Assistant Secretary for Preparedness and Response (ASPR), an agency of the U.S. Department of Health and Human Services (HHS)
Value: approximately $120 million
Effective: 2023-05-26

Exact text from the filing

On May 26, 2023, Emergent BioSolutions Inc. (including its wholly-owned subsidiaries, “Emergent”), through its wholly-owned subsidiary, Emergent Product Development Gaithersburg Inc., received a contract modification from the Office of the Assistant Secretary for Preparedness and Response (“ASPR”), an agency of the U.S. Department of Health and Human Services (“HHS”), exercising and funding the third of nine annual contract term extension options (the “Third Option Exercise”) for Emergent to supply ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) into the U.S. Strategic National Stockpile (the “SNS”). The Third Option Exercise is valued at approximately $120 million.

View on SEC.gov

Browse all material agreements →

Emergent BioSolutions Inc. filing history →

Source: SEC EDGAR

accession 0001367644-23-000094

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.